Well-known pharmaceutical companies change owners

On December 20, according to Xinhua News, Tianjin Jinlian Investment Holdings Co., Ltd. ("Tianjin Union Holdings") and Shanghai Industrial Group Co., Ltd. ("Ssingshi Group"), held a signing ceremony for Tianjin Pharmaceutical Group's mixed reform at the Wanli Tianjin Hotel, marking a major achievement of Tianjin Pharmaceutical Group's mixed reform.
it is understood that on September 29, 2020, Tianjin Pharmaceutical Mixed Reform Project was publicly listed and traded in Tianjin Property Rights Trading Center, and Tianjin, Shanghai and Shenzhen Biopharmaceutical Technology Co., Ltd. won 67% of the shares of Pharmaceutical Group.
Shanghai Shi Group to participate in the pharmaceutical group mixed reform, led the establishment of Tianjin, Shanghai and Shenzhen Biopharmaceutical Technology Co., Ltd., registered capital of 5 billion yuan.
Tianjin Pharmaceutical Group is a large state-owned integrated pharmaceutical group, formerly known as the Tianjin Pharmaceutical Administration, founded in 1979, after more than 40 years of development, has formed five business sectors, scientific research, production, commercial sales integrated operation, with GlaxoSmithKline, Otsuka and other multinational well-known pharmaceutical companies to form more than 10 joint ventures, for many years selected in the top 500 Chinese enterprises, China's pharmaceutical industry top 100.
, which was established in Hong Kong in July 1981, is currently whositablely owned by the Shanghai State-owned Assets Supervision and Administration Commission and covers five major areas: pharmaceutical and medical, infrastructure and environmental protection, real estate and regional development, consumer goods, financial services and investment.
Group owns five domestic and foreign listed companies, including Shanghai Pharmaceutical Group Co., Ltd.
enterprise officials said that the mixed reform will promote Tianjin Pharmaceutical Group to improve the modern enterprise system and corporate governance structure, enhance Tianjin Pharmaceutical Group's scientific and technological innovation and market-oriented operation capacity, promote Tianjin Pharmaceutical Group based on the main industry, rooted in Tianjin, to achieve transformation and upgrading, tianjin pharmaceutical and health industry development into a "new impetus."
Tianjin Pharmaceuticals, Shanghai Pharmaceuticals to cooperate Tianjin Pharmaceuticals official website shows that at present, Tianjin Pharmaceuticals has more than 180 enterprises, holding china New Pharmaceuticals, Tian Pharmaceutical shares, Lisheng Pharmaceuticals three listed companies and Mida Technology, a new three-board listed company.
Among them, the Group's product resources are rich, in the production of more than 1300 kinds of products, covering Chinese medicine, chemical drugs, biological vaccines, medical devices and other categories, corticosteroid raw materials pharmaceutical production capacity ranked in the forefront of the world, pharmaceutical amino acid raw materials production and sales of domestic leading, quick-acting heart-saving pills, Shoubishan, Jingwan red ointment, through the pulse heart pills, Yudr and a large number of widely known and reputation of the "big varieties" sold at home and abroad.
In addition, the Group also has "Da Rentang", "Long Shun-tang", "Le Rentang" and other 6 old Chinese characters, "Shuangyan", "Songbai", "biochemical" and other 14 well-known trademarks in China, the total number of the country's pharmaceutical industry.
Tianjin Pharmaceutical Group Party Secretary and Chairman Lu Yanchang said in an interview with the media: Tianjin Pharmaceutical Group has advantages, but there are many shortcomings in the development, with the development of enterprises, the existing institutional mechanisms for enterprises still have constraints, such as market development and capital operation.
And Shanghai Real Group has more successful experience in the reform of state-owned enterprises and capital markets - its 2008 asset restructuring of Shanghai Pharmaceutical Group has now produced fruitful results, the future success of Shanghai Pharmaceutical Group experience will also be applied to Tianjin Pharmaceutical Group.
said that in the future, Tianjin Pharmaceutical Group will be integrated into the supply chain of Shanghai Pharmaceuticals, and further improve Tianjin Pharmaceuticals research and development investment.
means that in the near future, the two well-known pharmaceutical companies will be more closely linked and will further establish cooperative relations.
in fact, in recent years, promoting the reform of state-owned enterprises has been listed as a priority task of the government, since 2015, the state issued a number of documents, to a certain extent, to promote the reform of mixed ownership of pharmaceutical enterprises.
the impact on the pharmaceutical industry? According to Guoxin Securities statistics, A-share pharmaceutical listed companies have 47 state-owned enterprises, state-owned enterprises (National Pharmaceutical Department, China Resources Department, General Department) 10, local state-owned enterprises (Pharmacy Department, Tian Medicine Department, Taiji Department, Ha Pharmaceutical Department) 33, school-run enterprises (Tsinghua, Peking University, China University, etc.) 4.
the pace of state-owned enterprises to carry out mixed ownership reform is not the same: the state medicine at the subsidiary level earlier to achieve mixed reform, Yunnan white medicine introduced private capital and carried out executive compensation reform, ha medicine injected social capital ... The Pharmaceutical Economics Daily has written that the pharmaceutical industry is a relatively full field of private enterprises, in the pharmaceutical business, the proportion of state-owned enterprises is large.
And pharmaceutical commercial enterprises generally face the problem of long repayment cycle, large capital consumption, the introduction of strategic investment can significantly reduce the company's financial leverage, ease the pressure on capital operation, and pharmaceutical business in line with the policy of "commercial competitive industry" standards, is expected to take the lead in the mixed reform.
especially in circulation enterprises, many commercial companies have a state-owned background, in the channel will have advantages, state-owned capital based on such advantages and a larger volume, will go a little higher.
There is a view in the industry that the original intention of the mixed reform is to improve efficiency and stimulate the vitality of enterprises through the introduction of social capital, many biopharmaceutical enterprises also show a variety of equity structure, including equity balance, social capital holding, etc. , the results of mixed reform, can wait for time and market testing.
。